Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.83 |
| ▸ | TUBB | P07437 | 4/20 | 0.83 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.83 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.83 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.83 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.83 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.83 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.83 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.83 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.83 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.83 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.83 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.83 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.83 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | P4HB | P07237 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22651647 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10063820 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22372700 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22580752 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21127723 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16128978 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13667605 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21729001 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20822457 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17349736 | 1.00 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
| US-11241503-B2 | Oxadiazole linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20210299265-A1 | EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210154320-A1 | OXADIAZOLE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-3302570-B1 | TRIMALEIMIDE LINKERS AND USES THEREOF | NEWBIO THERAPEUTICS INC (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-10960082-B2 | Tridentate connexon and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2021-03-30 | — | — | US | disclosed |
| EP-3303366-B1 | DERIVATIVES OF DOLASTATIN 10 AND USES THEREOF | NEWBIO THERAPEUTICS INC (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-20130029900-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7851432-B2 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7301019-B2 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301019-B2 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | SPR, SDAD1, ARRB1 | TUBB4A 548/4885TUBB 703/4885TUBA3C 1070/4885 |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | TUBB4A 2306/4885TUBB 2899/4885TUBA3C 3933/4885 |
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | TUBB4A 940/4885TUBB 997/4885TUBA3C 972/4885 |
| US-20210299265-A1 | EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES | EPCAM, CD47, CKAP4 | TUBB4A 150/4885TUBB 314/4885TUBA3C 392/4885 |
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DARS1, CD2, FCGR2A | TUBB4A 940/4885TUBB 997/4885TUBA3C 972/4885 |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | TUBB4A 375/4885TUBB 737/4885TUBA3C 975/4885 |
| US-10960082-B2 | Tridentate connexon and use thereof | DNTT, CD2, CLTA | TUBB4A 1511/4885TUBB 1101/4885TUBA3C 998/4885 |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | MCTS1, CA14, TTL | TUBB4A 103/4885TUBB 56/4885TUBA3C 142/4885 |
| US-11241503-B2 | Oxadiazole linkers and use thereof | OXA1L, CD99, IGLV6-57 | TUBB4A 299/4885TUBB 153/4885TUBA3C 213/4885 |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | TUBB4A 375/4885TUBB 737/4885TUBA3C 975/4885 |
| US-20210154320-A1 | OXADIAZOLE LINKERS AND USE THEREOF | OXA1L, CD99, IGLV6-57 | TUBB4A 299/4885TUBB 153/4885TUBA3C 213/4885 |
| US-20130029900-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | VIP, HDGF, NGLY1 | TUBB4A 1317/4885TUBB 2289/4885TUBA3C 2722/4885 |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | MCTS1, CA14, TTL | TUBB4A 103/4885TUBB 56/4885TUBA3C 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.